
    
      A Phase I Open-Label, 2-Part, 3-Cohort, Single-Centre Study to Assess the Concentration of
      Avibactam and Ceftazidime in Epithelial Lining Fluid and Plasma Using at Least Two Different
      Dosing Regimens in Healthy Volunteers
    
  